CMP-002
CMP-SYNGAP-01- SYNGAP1-Related Disorders
Market cap $251M 62.8M shares (10-Q, Nov 4, 2026) × $4.00 close Nov 17, 2026
Most recent annual filing: 2026-03-05
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Regulatory RNA Amplification Platform — maps regulatory RNAs (regRNAs) and generates ASO therapeutic candidates targeting regRNAs associated with haploinsufficient and recessive partial loss-of-function genetic disorders; disease focus spans more than 1,200 such disorders where modest protein upregulation may be clinically meaningful.
Targets: regRNAs, regRNA
Regulatory RNA-targeting ASO platform that maps regulatory RNAs (regRNAs) acting on transcription factors to identify therapeutic candidates designed to upregulate gene expression in haploinsufficient and recessive partial loss-of-function genetic disorders; disease focus includes neurodegenerative and kidney disease indications via GSK collaboration.
Targets: regRNAs
Proprietary regRNA mapping and ASO discovery platform that identifies and characterizes regulatory RNAs controlling protein-coding genes, enabling design of ASO therapeutics to upregulate gene expression. Primary focus on CNS haploinsufficient diseases; also being extended to neurodegenerative, kidney, liver, heart, skeletal muscle, and immune system disease areas via collaboration with GSK.
RNA-regulating therapeutic platform used to identify and develop product candidates for a broad range of genetic diseases. Used as the basis for the GSK collaboration and license agreement.
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Every verdict Biotech Distilled has published on Camp4 Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →